ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
  • Category
  • Region
U.S. (TOLL FREE)
+1 (315) 215-3225
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neuroblastoma Treatment Drugs Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-26Y10721
Home | Market Reports | Health| Health Conditions| Cancer
Global Neuroblastoma Treatment Drugs Market Research Report 2022
BUY CHAPTERS

Global Neuroblastoma Treatment Drugs Market Research Report 2025

Code: QYRE-Auto-26Y10721
Report
January 2025
Pages:81
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
United Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer Inc
Hikma Pharmaceuticals
Teva Pharmaceuticals
Y-mAbs Therapeutics

Neuroblastoma Treatment Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Neuroblastoma Treatment Drugs Market

Neuroblastoma Treatment Drugs Market

The global market for Neuroblastoma Treatment Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient"s age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The market for neuroblastoma treatment drugs is showing steady growth, benefiting from advances in medical technology and research. The market size is gradually expanding, with drug sales increasing year by year. These drugs have specific uses in neuroblastoma patients, primarily aiming to reduce tumor volume, alleviate symptoms, and enhance survival rates by targeting tumor cells. Future developments may involve more personalized treatment approaches, combining targeted therapies and immunotherapies to improve efficacy while minimizing adverse drug reactions.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Neuroblastoma Treatment Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroblastoma Treatment Drugs.
The Neuroblastoma Treatment Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuroblastoma Treatment Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuroblastoma Treatment Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Neuroblastoma Treatment Drugs Market Report

Report Metric Details
Report Name Neuroblastoma Treatment Drugs Market
CAGR 5%
Segment by Type
  • Cyclophosphamide
  • Dinutuximab
  • Naxitamab
  • Doxorubicin Hydrochloride
  • Vincristine Sulfate
  • Other
Segment by Application
  • Hospital
  • Clinic
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals, Teva Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Neuroblastoma Treatment Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Neuroblastoma Treatment Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Neuroblastoma Treatment Drugs Market report?

Ans: The main players in the Neuroblastoma Treatment Drugs Market are United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals, Teva Pharmaceuticals

What are the Application segmentation covered in the Neuroblastoma Treatment Drugs Market report?

Ans: The Applications covered in the Neuroblastoma Treatment Drugs Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Neuroblastoma Treatment Drugs Market report?

Ans: The Types covered in the Neuroblastoma Treatment Drugs Market report are Cyclophosphamide, Dinutuximab, Naxitamab, Doxorubicin Hydrochloride, Vincristine Sulfate, Other

1 Neuroblastoma Treatment Drugs Market Overview
1.1 Product Definition
1.2 Neuroblastoma Treatment Drugs by Type
1.2.1 Global Neuroblastoma Treatment Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Cyclophosphamide
1.2.3 Dinutuximab
1.2.4 Naxitamab
1.2.5 Doxorubicin Hydrochloride
1.2.6 Vincristine Sulfate
1.2.7 Other
1.3 Neuroblastoma Treatment Drugs by Application
1.3.1 Global Neuroblastoma Treatment Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Neuroblastoma Treatment Drugs Market Size Estimates and Forecasts
1.4.1 Global Neuroblastoma Treatment Drugs Revenue 2020-2031
1.4.2 Global Neuroblastoma Treatment Drugs Sales 2020-2031
1.4.3 Global Neuroblastoma Treatment Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Neuroblastoma Treatment Drugs Market Competition by Manufacturers
2.1 Global Neuroblastoma Treatment Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Neuroblastoma Treatment Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Neuroblastoma Treatment Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Neuroblastoma Treatment Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Neuroblastoma Treatment Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neuroblastoma Treatment Drugs, Product Type & Application
2.7 Global Key Manufacturers of Neuroblastoma Treatment Drugs, Date of Enter into This Industry
2.8 Global Neuroblastoma Treatment Drugs Market Competitive Situation and Trends
2.8.1 Global Neuroblastoma Treatment Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Neuroblastoma Treatment Drugs Players Market Share by Revenue
2.8.3 Global Neuroblastoma Treatment Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Neuroblastoma Treatment Drugs Market Scenario by Region
3.1 Global Neuroblastoma Treatment Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Neuroblastoma Treatment Drugs Sales by Region: 2020-2031
3.2.1 Global Neuroblastoma Treatment Drugs Sales by Region: 2020-2025
3.2.2 Global Neuroblastoma Treatment Drugs Sales by Region: 2026-2031
3.3 Global Neuroblastoma Treatment Drugs Revenue by Region: 2020-2031
3.3.1 Global Neuroblastoma Treatment Drugs Revenue by Region: 2020-2025
3.3.2 Global Neuroblastoma Treatment Drugs Revenue by Region: 2026-2031
3.4 North America Neuroblastoma Treatment Drugs Market Facts & Figures by Country
3.4.1 North America Neuroblastoma Treatment Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Neuroblastoma Treatment Drugs Sales by Country (2020-2031)
3.4.3 North America Neuroblastoma Treatment Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Neuroblastoma Treatment Drugs Market Facts & Figures by Country
3.5.1 Europe Neuroblastoma Treatment Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Neuroblastoma Treatment Drugs Sales by Country (2020-2031)
3.5.3 Europe Neuroblastoma Treatment Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neuroblastoma Treatment Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Neuroblastoma Treatment Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Neuroblastoma Treatment Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Neuroblastoma Treatment Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Neuroblastoma Treatment Drugs Market Facts & Figures by Country
3.7.1 Latin America Neuroblastoma Treatment Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Neuroblastoma Treatment Drugs Sales by Country (2020-2031)
3.7.3 Latin America Neuroblastoma Treatment Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neuroblastoma Treatment Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Neuroblastoma Treatment Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Neuroblastoma Treatment Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Neuroblastoma Treatment Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Neuroblastoma Treatment Drugs Sales by Type (2020-2031)
4.1.1 Global Neuroblastoma Treatment Drugs Sales by Type (2020-2025)
4.1.2 Global Neuroblastoma Treatment Drugs Sales by Type (2026-2031)
4.1.3 Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2020-2031)
4.2 Global Neuroblastoma Treatment Drugs Revenue by Type (2020-2031)
4.2.1 Global Neuroblastoma Treatment Drugs Revenue by Type (2020-2025)
4.2.2 Global Neuroblastoma Treatment Drugs Revenue by Type (2026-2031)
4.2.3 Global Neuroblastoma Treatment Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Neuroblastoma Treatment Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Neuroblastoma Treatment Drugs Sales by Application (2020-2031)
5.1.1 Global Neuroblastoma Treatment Drugs Sales by Application (2020-2025)
5.1.2 Global Neuroblastoma Treatment Drugs Sales by Application (2026-2031)
5.1.3 Global Neuroblastoma Treatment Drugs Sales Market Share by Application (2020-2031)
5.2 Global Neuroblastoma Treatment Drugs Revenue by Application (2020-2031)
5.2.1 Global Neuroblastoma Treatment Drugs Revenue by Application (2020-2025)
5.2.2 Global Neuroblastoma Treatment Drugs Revenue by Application (2026-2031)
5.2.3 Global Neuroblastoma Treatment Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Neuroblastoma Treatment Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 United Therapeutics
6.1.1 United Therapeutics Company Information
6.1.2 United Therapeutics Description and Business Overview
6.1.3 United Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 United Therapeutics Neuroblastoma Treatment Drugs Product Portfolio
6.1.5 United Therapeutics Recent Developments/Updates
6.2 Y-mAbs Therapeutics
6.2.1 Y-mAbs Therapeutics Company Information
6.2.2 Y-mAbs Therapeutics Description and Business Overview
6.2.3 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product Portfolio
6.2.5 Y-mAbs Therapeutics Recent Developments/Updates
6.3 EUSA Pharma
6.3.1 EUSA Pharma Company Information
6.3.2 EUSA Pharma Description and Business Overview
6.3.3 EUSA Pharma Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 EUSA Pharma Neuroblastoma Treatment Drugs Product Portfolio
6.3.5 EUSA Pharma Recent Developments/Updates
6.4 ANI Pharmaceuticals
6.4.1 ANI Pharmaceuticals Company Information
6.4.2 ANI Pharmaceuticals Description and Business Overview
6.4.3 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolio
6.4.5 ANI Pharmaceuticals Recent Developments/Updates
6.5 Baxter Healthcare
6.5.1 Baxter Healthcare Company Information
6.5.2 Baxter Healthcare Description and Business Overview
6.5.3 Baxter Healthcare Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Baxter Healthcare Neuroblastoma Treatment Drugs Product Portfolio
6.5.5 Baxter Healthcare Recent Developments/Updates
6.6 Ingenus Pharmaceuticals
6.6.1 Ingenus Pharmaceuticals Company Information
6.6.2 Ingenus Pharmaceuticals Description and Business Overview
6.6.3 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolio
6.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
6.7 Pfizer
6.7.1 Pfizer Company Information
6.7.2 Pfizer Description and Business Overview
6.7.3 Pfizer Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Pfizer Neuroblastoma Treatment Drugs Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Hikma Pharmaceuticals
6.8.1 Hikma Pharmaceuticals Company Information
6.8.2 Hikma Pharmaceuticals Description and Business Overview
6.8.3 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolio
6.8.5 Hikma Pharmaceuticals Recent Developments/Updates
6.9 Teva Pharmaceuticals
6.9.1 Teva Pharmaceuticals Company Information
6.9.2 Teva Pharmaceuticals Description and Business Overview
6.9.3 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolio
6.9.5 Teva Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neuroblastoma Treatment Drugs Industry Chain Analysis
7.2 Neuroblastoma Treatment Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neuroblastoma Treatment Drugs Production Mode & Process Analysis
7.4 Neuroblastoma Treatment Drugs Sales and Marketing
7.4.1 Neuroblastoma Treatment Drugs Sales Channels
7.4.2 Neuroblastoma Treatment Drugs Distributors
7.5 Neuroblastoma Treatment Drugs Customer Analysis
8 Neuroblastoma Treatment Drugs Market Dynamics
8.1 Neuroblastoma Treatment Drugs Industry Trends
8.2 Neuroblastoma Treatment Drugs Market Drivers
8.3 Neuroblastoma Treatment Drugs Market Challenges
8.4 Neuroblastoma Treatment Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
United Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer Inc
Hikma Pharmaceuticals
Teva Pharmaceuticals
Y-mAbs Therapeutics
List of Tables
 Table 1. Global Neuroblastoma Treatment Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Neuroblastoma Treatment Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Neuroblastoma Treatment Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Neuroblastoma Treatment Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Neuroblastoma Treatment Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Neuroblastoma Treatment Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Neuroblastoma Treatment Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Neuroblastoma Treatment Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Neuroblastoma Treatment Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Neuroblastoma Treatment Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Neuroblastoma Treatment Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Neuroblastoma Treatment Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Neuroblastoma Treatment Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroblastoma Treatment Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Neuroblastoma Treatment Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Neuroblastoma Treatment Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Neuroblastoma Treatment Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Neuroblastoma Treatment Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Neuroblastoma Treatment Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Neuroblastoma Treatment Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Neuroblastoma Treatment Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Neuroblastoma Treatment Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Neuroblastoma Treatment Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Neuroblastoma Treatment Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Neuroblastoma Treatment Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Neuroblastoma Treatment Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Neuroblastoma Treatment Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Neuroblastoma Treatment Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Neuroblastoma Treatment Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Neuroblastoma Treatment Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Neuroblastoma Treatment Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Neuroblastoma Treatment Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Neuroblastoma Treatment Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Neuroblastoma Treatment Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Neuroblastoma Treatment Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Neuroblastoma Treatment Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Neuroblastoma Treatment Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Neuroblastoma Treatment Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Neuroblastoma Treatment Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Neuroblastoma Treatment Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Neuroblastoma Treatment Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Neuroblastoma Treatment Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Neuroblastoma Treatment Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Neuroblastoma Treatment Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Neuroblastoma Treatment Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Neuroblastoma Treatment Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Neuroblastoma Treatment Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Neuroblastoma Treatment Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Neuroblastoma Treatment Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Neuroblastoma Treatment Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Neuroblastoma Treatment Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Neuroblastoma Treatment Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Neuroblastoma Treatment Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Neuroblastoma Treatment Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Neuroblastoma Treatment Drugs Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Neuroblastoma Treatment Drugs Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Neuroblastoma Treatment Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Neuroblastoma Treatment Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Neuroblastoma Treatment Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Neuroblastoma Treatment Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Neuroblastoma Treatment Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Neuroblastoma Treatment Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Neuroblastoma Treatment Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Neuroblastoma Treatment Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Neuroblastoma Treatment Drugs Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Neuroblastoma Treatment Drugs Price (US$/Unit) by Application (2026-2031)
 Table 70. United Therapeutics Company Information
 Table 71. United Therapeutics Description and Business Overview
 Table 72. United Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. United Therapeutics Neuroblastoma Treatment Drugs Product
 Table 74. United Therapeutics Recent Developments/Updates
 Table 75. Y-mAbs Therapeutics Company Information
 Table 76. Y-mAbs Therapeutics Description and Business Overview
 Table 77. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product
 Table 79. Y-mAbs Therapeutics Recent Developments/Updates
 Table 80. EUSA Pharma Company Information
 Table 81. EUSA Pharma Description and Business Overview
 Table 82. EUSA Pharma Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. EUSA Pharma Neuroblastoma Treatment Drugs Product
 Table 84. EUSA Pharma Recent Developments/Updates
 Table 85. ANI Pharmaceuticals Company Information
 Table 86. ANI Pharmaceuticals Description and Business Overview
 Table 87. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product
 Table 89. ANI Pharmaceuticals Recent Developments/Updates
 Table 90. Baxter Healthcare Company Information
 Table 91. Baxter Healthcare Description and Business Overview
 Table 92. Baxter Healthcare Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Baxter Healthcare Neuroblastoma Treatment Drugs Product
 Table 94. Baxter Healthcare Recent Developments/Updates
 Table 95. Ingenus Pharmaceuticals Company Information
 Table 96. Ingenus Pharmaceuticals Description and Business Overview
 Table 97. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product
 Table 99. Ingenus Pharmaceuticals Recent Developments/Updates
 Table 100. Pfizer Company Information
 Table 101. Pfizer Description and Business Overview
 Table 102. Pfizer Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Pfizer Neuroblastoma Treatment Drugs Product
 Table 104. Pfizer Recent Developments/Updates
 Table 105. Hikma Pharmaceuticals Company Information
 Table 106. Hikma Pharmaceuticals Description and Business Overview
 Table 107. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product
 Table 109. Hikma Pharmaceuticals Recent Developments/Updates
 Table 110. Teva Pharmaceuticals Company Information
 Table 111. Teva Pharmaceuticals Description and Business Overview
 Table 112. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product
 Table 114. Teva Pharmaceuticals Recent Developments/Updates
 Table 115. Key Raw Materials Lists
 Table 116. Raw Materials Key Suppliers Lists
 Table 117. Neuroblastoma Treatment Drugs Distributors List
 Table 118. Neuroblastoma Treatment Drugs Customers List
 Table 119. Neuroblastoma Treatment Drugs Market Trends
 Table 120. Neuroblastoma Treatment Drugs Market Drivers
 Table 121. Neuroblastoma Treatment Drugs Market Challenges
 Table 122. Neuroblastoma Treatment Drugs Market Restraints
 Table 123. Research Programs/Design for This Report
 Table 124. Key Data Information from Secondary Sources
 Table 125. Key Data Information from Primary Sources
 Table 126. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Neuroblastoma Treatment Drugs
 Figure 2. Global Neuroblastoma Treatment Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Neuroblastoma Treatment Drugs Market Share by Type: 2024 & 2031
 Figure 4. Cyclophosphamide Product Picture
 Figure 5. Dinutuximab Product Picture
 Figure 6. Naxitamab Product Picture
 Figure 7. Doxorubicin Hydrochloride Product Picture
 Figure 8. Vincristine Sulfate Product Picture
 Figure 9. Other Product Picture
 Figure 10. Global Neuroblastoma Treatment Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 11. Global Neuroblastoma Treatment Drugs Market Share by Application: 2024 & 2031
 Figure 12. Hospital
 Figure 13. Clinic
 Figure 14. Other
 Figure 15. Global Neuroblastoma Treatment Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Neuroblastoma Treatment Drugs Market Size (2020-2031) & (US$ Million)
 Figure 17. Global Neuroblastoma Treatment Drugs Sales (2020-2031) & (K Units)
 Figure 18. Global Neuroblastoma Treatment Drugs Average Price (US$/Unit) & (2020-2031)
 Figure 19. Neuroblastoma Treatment Drugs Report Years Considered
 Figure 20. Neuroblastoma Treatment Drugs Sales Share by Manufacturers in 2024
 Figure 21. Global Neuroblastoma Treatment Drugs Revenue Share by Manufacturers in 2024
 Figure 22. Global 5 and 10 Largest Neuroblastoma Treatment Drugs Players: Market Share by Revenue in Neuroblastoma Treatment Drugs in 2024
 Figure 23. Neuroblastoma Treatment Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Global Neuroblastoma Treatment Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 25. North America Neuroblastoma Treatment Drugs Sales Market Share by Country (2020-2031)
 Figure 26. North America Neuroblastoma Treatment Drugs Revenue Market Share by Country (2020-2031)
 Figure 27. U.S. Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Canada Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Europe Neuroblastoma Treatment Drugs Sales Market Share by Country (2020-2031)
 Figure 30. Europe Neuroblastoma Treatment Drugs Revenue Market Share by Country (2020-2031)
 Figure 31. Germany Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. France Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. U.K. Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Italy Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Russia Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Asia Pacific Neuroblastoma Treatment Drugs Sales Market Share by Region (2020-2031)
 Figure 37. Asia Pacific Neuroblastoma Treatment Drugs Revenue Market Share by Region (2020-2031)
 Figure 38. China Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Japan Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. South Korea Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. India Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Australia Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Taiwan Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Indonesia Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Thailand Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Malaysia Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Philippines Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Latin America Neuroblastoma Treatment Drugs Sales Market Share by Country (2020-2031)
 Figure 49. Latin America Neuroblastoma Treatment Drugs Revenue Market Share by Country (2020-2031)
 Figure 50. Mexico Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Brazil Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Argentina Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Middle East and Africa Neuroblastoma Treatment Drugs Sales Market Share by Country (2020-2031)
 Figure 54. Middle East and Africa Neuroblastoma Treatment Drugs Revenue Market Share by Country (2020-2031)
 Figure 55. Turkey Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Saudi Arabia Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. U.A.E Neuroblastoma Treatment Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Global Sales Market Share of Neuroblastoma Treatment Drugs by Type (2020-2031)
 Figure 59. Global Revenue Market Share of Neuroblastoma Treatment Drugs by Type (2020-2031)
 Figure 60. Global Neuroblastoma Treatment Drugs Price (US$/Unit) by Type (2020-2031)
 Figure 61. Global Sales Market Share of Neuroblastoma Treatment Drugs by Application (2020-2031)
 Figure 62. Global Revenue Market Share of Neuroblastoma Treatment Drugs by Application (2020-2031)
 Figure 63. Global Neuroblastoma Treatment Drugs Price (US$/Unit) by Application (2020-2031)
 Figure 64. Neuroblastoma Treatment Drugs Value Chain
 Figure 65. Channels of Distribution (Direct Vs Distribution)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Kidney Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-38R2107
Fri Mar 14 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Radiotherapy Positioning Products Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34T16080
Fri Mar 14 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Radiation Oncology Devices Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35A12535
Thu Mar 13 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Kidney Cancer Targeted Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-24A14985
Thu Mar 13 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions